30-day average of 15 articles · scale −100 to +100
Across 15 scored articles from Oct 17 to Nov 15, 2026 (UTC),
the average sentiment of Amgen news is Somewhat Bullish (+44)
on a scale from −100 to +100.
That is up 10 points from the previous 30 days (+34).
📊 Amgen reported $38.9B revenue and $9.4B net income for fiscal 2026.
🏦 Company maintained 6.3x debt-to-equity ratio with $8.1B free cash flow.
Slightly Bullish +25
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
AI-generated analysis
Key insights
📊 Amgen reported revenue of approximately $38.9 billion and net income of nearly $9.4 billion for the 12 months ended Sept. 30, 2026.
🏦 The company maintained a debt-to-equity ratio of roughly 6.3x and generated free cash flow of about $8.1 billion as of Dec. 31, 2025.
📈 Amgen is projected to achieve roughly 3% revenue growth in fiscal 2026, reaching around $37.8 billion despite being a mature business.
🤝 Amgen reached a deal with the U.S. government to lower prices on key drugs Aimovig and Amjevita in exchange for tariff exemptions for three years.
🏭 Nearly 77% of Amgen's revenues in 2025 came from sales to three large distributors: McKesson, Cencora, and Cardinal Health.
💊 The company possesses six drug franchises that generate $1 billion-plus in annual revenue, providing a stable cash flow base.
📉 Amgen is characterized as an affordable option for value-conscious investors based on its significantly lower Forward P/E and P/S ratios.
📈 Bullish signals
💊Amgen maintains a diversified portfolio across oncology and rare diseases, providing a steady business model with six drug franchises generating over $1 billion in annual revenue each.
📈The company is projected to achieve roughly 3% revenue growth in fiscal 2026, reaching around $37.8 billion, supported by its massive scale and cash generation capabilities.
🤝Amgen secured a strategic deal with the U.S. government to lower prices on key drugs Aimovig and Amjevita in exchange for exemption from pharmaceutical tariffs for three years.
📉 Risk factors
📉The company faces substantial competition from biosimilars and generics, which can erode the market share of its older products.
📉Operational risks include a heavy reliance on specific manufacturing facilities in Puerto Rico and California.
Article
The article compares Amgen (AMGN) and Vertex Pharmaceuticals (VRTX), highlighting Amgen's diversified business model across oncology and rare diseases versus Vertex's high-growth specialization in genetic conditions. It notes that Amgen sells primarily through three large distributors, which accounted for nearly 77% of its revenues in 2025, adding a layer of customer concentration risk to the business.
Financial data reveals that in the 12 months ended Sept. 30, 2026, Amgen generated revenue of approximately $38.9 billion and net income of nearly $9.4 billion. The company maintains a debt-to-equity ratio of roughly 6.3x and produced free cash flow of about $8.1 billion for the fiscal year ended Dec. 31, 2025.
Amgen faces competition from biosimilars and pricing pressure but is positioned to achieve roughly 3% revenue growth in 2026, reaching around $37.8 billion. The company recently reached a deal with the U.S. government to lower prices on key drugs like Aimovig and Amjevita in exchange for exemption from pharmaceutical tariffs for three years.
Analysts view Amgen as an affordable option for value-conscious investors due to its lower Forward P/E and P/S ratios compared to Vertex. While not a fast-growing company by sales, its scale allows it to pursue future growth through acquisitions, supported by six drug franchises generating over $1 billion in annual revenue each.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
For the quarter ended March 2026, Amgen (AMGN) reported total revenue of $8.62 billion, marking a 5.8% increase over the same period last year. The company delivered earnings per share (EPS) of $5.15, compared to $4.90 in the year-ago quarter. Both figures surpassed Wall Street expectations, with revenue exceeding the Zacks Consensus Estimate of $8.47 billion by +1.71% and EPS beating the consensus estimate of $4.73 by +8.87%.
Detailed product sales data revealed mixed performance across Amgen's key offerings. Repatha emerged as a standout performer, with total sales reaching $876 million compared to an analyst average of $819.8 million, representing a +33.5% year-over-year change. Nplate also showed strong growth with total sales of $412 million versus estimates of $339.63 million, a +31.6% increase. Conversely, Enbrel faced significant headwinds, reporting total sales of $320 million against an analyst average of $426.94 million, reflecting a -37.3% decline from the prior year. XGEVA total sales dropped by 27.4% to $411 million versus estimated figures, while Prolia sales fell 33.9% year-over-year to $727 million.
Following the earnings release, Amgen shares declined -4.3% over the past month, contrasting with the Zacks S&P 500 composite's +12.2% gain. The stock currently holds a Zacks Rank #3 (Hold), suggesting expectations of performance in line with the broader market. While the article notes that radical new technology such as quantum computing is emerging, this specific section serves as an advertisement for unrelated investment reports and does not impact Amgen's financial results or current market position.
📈 Amgen revenue hit $8.62B, beating estimates with a 5.8% year-over-year increase.
💊 Key drugs diverged sharply as Repatha grew while Enbrel and XGEVA declined.
📉 Shares fell -4.3% despite earnings beats, prompting analysts to rate the stock Hold.
📊 Amgen (AMGN) reported Q1 2026 revenue of $8.62 billion, a 5.8% increase year-over-year.
💰 Earnings per share reached $5.15, surpassing the analyst consensus estimate of $4.73 with an 8.87% surprise.
📈 Repatha generated total product sales of $876 million, exceeding estimates by 33.5% year-over-year.
⚠️ Enbrel showed a significant decline in performance with total sales of $320 million compared to a 37.3% drop from the previous year.
📉 Prolia reported total sales of $727 million, reflecting a 33.9% decrease year-over-year despite analyst estimates of $831.86 million.
💊 BLINCYTO demonstrated strong growth in ROW markets with sales of $194 million against an estimate of $118.06 million.
🇺🇸 Nplate showed positive momentum in the U.S. market with revenue of $283 million, up 40.8% from last year.
📉 XGEVA declined in the U.S. region to $228 million, which is -36.7% lower than the same period last year.
📊 Amgen's stock returned -4.3% over the past month compared to the S&P 500's gain of +12.2%.
⚖️ The company holds a Zacks Rank #3 (Hold), suggesting potential performance aligned with the broader market.
🔬 The article highlights various other drugs like Vectibix, KYPROLIS, and Nplate alongside their specific sales figures and estimates.
🌐 Amgen's total revenue beat the consensus estimate of $8.47 billion by 1.71%.
⏱️ Repatha sales in international regions (ROW) rose to $411 million, representing a 31.3% increase from last year.
💻 The article transitions into unrelated promotional content about quantum computing and other stocks like Lightspeed Commerce.
📄 The report is attributed to Zacks Investment Research, which emphasizes earnings estimate revisions as a driver for stock prices.
Bullish Signals
Amgen reported revenue of $8.62 billion for Q1 2026, representing a positive 5.8% increase year-over-year.
The company beat Wall Street expectations on both fronts, delivering a +1.71% revenue surprise and an impressive +8.87% EPS surprise.
Repatha sales in international regions (ROW) surged 31.3% year-over-year to $411 million, significantly exceeding the analyst consensus of $373.03 million.
BLINCYTO sales were a standout success story with a massive 100% year-over-year growth and total global sales of $415 million, beating estimates by seven analysts.
Nplate revenue grew over 31% year-over-year in both the U.S. and globally, demonstrating strong momentum in this new product segment.
Kymirs (Kyprolis) generated $328.67 million in sales, aligning closely with analyst estimates and showing stable demand.
Risk Factors
Amgen's stock returned -4.3% over the past month, significantly underperforming the Zacks S&P 500 composite which gained +12.2% during the same period.
Product sales for Enbrel- Total were $320 million, missing the seven-analyst average estimate of $426.94 million by approximately $107 million, representing a year-over-year decline of -37.3%.
Sales for XGEVA- U.S. ($228 million) fell short of the six-analyst average estimate of $238.6 million and saw revenue drop -36.7% year-over-year to $228 million versus the prior period.
Product sales for Prolia- Total reached $727 million, which is below the seven-analyst average estimate of $831.86 million, indicating a -33.9% year-over-year change.
XGEVA- Total sales ($411 million) underperformed the seven-analyst average estimate of $389.57 million and experienced a significant -27.4% decline compared to the year-ago quarter.
Amgen's shares are currently assigned a Zacks Rank #3 (Hold), suggesting analysts expect the stock to perform in line with the broader market rather than outperform.
Amgen reported a strong first quarter with revenue driven significantly by its six key growth drivers, which collectively generated nearly 70% of sales and grew 24% year-over-year. Standout performance was seen in its core franchise products, with Repatha sales reaching $876 million, up 34% to an annual run rate that management expects will sustain momentum through patent expiry; Evenity reached $562 million (up 27%), maintaining a 65% share of the U.S. bone builder market; and TEPEZZA sales climbed 29% to $490 million as demand grew in pulmonology and allergy, supported by new Phase III data for an on-body injector. The rare-disease portfolio also saw robust growth, rising 25% to $1.2 billion, largely propelled by Uplizna which surged 188% to $262 million as it solidified its position in neuromyelitis optica spectrum disorder.
Despite the positive product momentum, Amgen noted that certain franchises face headwinds from biosimilar competition and patent expirations. Prolia and Xgeva combined sales fell 32% year-over-year to $1.1 billion, with erosion expected to accelerate through 2026. Chief Commercial Officer Murdo Gordon clarified that while the "AmgenNow" cash-pay program is seeing interest in Repatha at $239 per month involving approximately 8,000 to 9,000 patients, this component represents a relatively small fraction of total volumes. The company continues to emphasize disciplined execution in late-stage R&D and product launches to offset these pressures, with 16 products posting double-digit sales growth and 17 annualizing at over $1 billion in sales.
Looking forward to fiscal 2026, Amgen raised its full-year guidance to revenue between $37.1 billion and $38.5 billion and non-GAAP EPS of $21.70 to $23.10, maintaining an expected non-GAAP operating margin of around 45%. CEO Robert Bradway described 2026 as a "springboard year" where rapidly growing products will help offset the impact of patent expirations and competitive pressures. However, management added a significant caveat that ongoing IRS audits and tax litigation could materially affect future results if adverse adjustments are sustained. In research highlights, Amgen expanded its Phase III MariTide program for obesity to include long-term maintenance dosing schedules and a 300-patient switching study from weekly GLP-1s, with early data suggesting improved tolerability through a three-step dose escalation.
📈 Top six drivers grew 24%, fueling nearly 70% of total sales.
💊 Repatha, Evenity, and TEPEZZA surged on guideline updates and new data.
⚠️ Guidance raised to $37.1B–$38.5B despite biosimilar erosion and IRS audits.
📈 Amgen reported a strong Q1 with its six key growth drivers growing collectively by 24% and accounting for nearly 70% of total sales.
💊 Repatha sales reached $876 million, up 34%, driven by updated guidelines and positive subgroup data showing reduced cardiovascular events in high-risk patients.
🦴 Evenity sales increased 27% to $562 million globally, holding a 65% share of the U.S. bone builder market with strong uptake in Japan.
💨 TEPEZZA sales climbed 29% to $490 million as endocrinology prescribing grew, supported by new Phase III data for a subcutaneous on-body injector.
🧬 Tepezza's rare-disease portfolio, led by Uplizna which surged 188%, saw total category growth of 25% to $1.2 billion across all approved indications.
📉 Prolia and Xgeva combined sales fell 32% year-over-year to $1.1 billion due to expected erosion from biosimilar competition through 2026.
💉 Innovative oncology portfolio grew 25% to $1.8 billion, highlighted by IMDELLTRA administration at over 1,800 U.S. sites and Bincyto growth.
🧬 Biosimilar sales rose 14% to $835 million, led by Pavblu which contributed $280 million with a prefilled syringe format valued by specialists.
💵 Repatha now has a cash-pay option available for approximately 8,000-9,000 patients at $239/month, though management notes this represents a small portion of volume.
🔬 Chief Scientific Officer Jay Bradner detailed the Phase III MariTide obesity program expansion into long-term maintenance dosing schedules (monthly/quarterly) to reduce treatment burden.
⚠️ Management raised full-year 2026 revenue guidance to $37.1–$38.5 billion and non-GAAP EPS to $21.70–$23.10 despite ongoing IRS audit uncertainties.
🛡️ Executives maintain a disciplined R&D strategy led by MariTide, aiming for products in 2026 to offset patent expirations and competitive pressures.
🗓️ A new Phase III switching study was launched to evaluate patients switching from weekly GLP-1s to MariTide under various dosing intervals.
🇯🇵 TEPEZZA plans additional global launches following its 2025 introduction in Japan, supported by growing prescriber interest and increased endocrinology adoption.
🚀 CEO Robert Bradway reiterated that 2026 is a "springboard year" designed to sustain growth through expanding franchises despite market headwinds.
Bullish Signals
Amgen delivered a strong Q1 with six key growth drivers accounting for nearly 70% of sales and collectively growing 24% year-over-year.
The rare-disease portfolio surged 25% to $1.2 billion, led by Uplizna which skyrocketed 188% to $262 million driven by strong uptake across all three approved indications.
Repatha sales reached $876 million, up 34%, bolstered by positive subgroup analysis showing a 31% reduction in cardiovascular events for high-risk patients with diabetes at the American College of Cardiology meeting.
Evenity sales rose 27% to $562 million with U.S. sales increasing 35% and maintaining a dominant 65% share of the U.S. bone builder market.
TEPEZZA sales climbed 29% to $490 million, supported by growth in the chronic rhinosinusitis indication and a new Phase III data point for an on-body injector supporting subcutaneous administration.
Innovative oncology portfolio sales grew 25% to $1.8 billion, with IMDELLTRA administered at over 1,800 U.S. sites and BLINCYTO sales up 12% to $415 million.
Biosimilars revenue increased 14% to $835 million, highlighted by Pavblu delivering $280 million in the quarter due to its prefilled syringe format and supply reliability.
Amgen raised full-year 2026 guidance to $37.1–$38.5B in revenues with a non-GAAP EPS target of $21.70–$23.10, signaling management confidence despite potential tax headwinds.
The MariTide Phase III program was expanded to include long-term maintenance dosing and a 300-patient switching study, reporting improved tolerability with flexible monthly/8-week/quarterly schedules.
Amgen anticipates accelerated pressure from biosimilars remains in line with expectations for Prolia and Xgeva, allowing management to focus resources on high-growth franchises.
Risk Factors
Ongoing IRS audits and tax litigation could materially affect future results if adjustments are sustained.
Prolia and Xgeva sales declined 32% year-over-year, with Amgen warning of accelerated pressure through the rest of 2026 due to increasing biosimilar competition.
TEPEZZA growth was partially offset by a 'burn in channel inventory'.
Amgen Inc. (AMGN), the Thousand Oaks, California-based biopharmaceutical company with an $182.4 billion market capitalization, has underperformed the broader market over the last year. While AMGN shares gained 17.1% during this period, the S&P 500 Index ($SPX) rallied nearly 28.3%. The performance gap is also evident against sector peers; the Invesco Pharmaceuticals ETF (PJP) has risen approximately 26.9% over the past year, whereas AMGN's year-to-date returns have surpassed PJP's recent losses, which stood at 1.3%. Despite this lag, AMGN stock has gained 3.3% in 2026 compared to the SPX's 4.2% YTD rise.
The company reported positive fourth-quarter results on February 3, with its shares closing up more than 8% following the announcement. Adjusted earnings per share (EPS) of $5.29 surpassed Wall Street expectations of $4.76, and revenue reached $9.9 billion, exceeding forecasts of $9.5 billion. For the full year, AMGN expects adjusted EPS between $21.60 and $23, with total revenue projected in the range of $37 billion to $38.4 billion. Analysts forecast that for fiscal 2026, ending in December, diluted EPS will grow 1.5% to $22.16, marking an impressive earnings surprise history where AMGN beat consensus estimates in each of the last four quarters.
Wall Street sentiment remains cautiously optimistic despite a recent shift in analyst ratings. Currently, 36 analysts cover AMGN stock with a consensus rating of "Moderate Buy," comprising 13 "Strong Buy" ratings, two "Moderate Buys," 18 "Holds," one "Moderate Sell," and two "Strong Sells." This distribution is less bullish than three months ago, when 14 analysts suggested a "Strong Buy" rating. On April 21, Canaccord Genuity initiated coverage with a "Hold" rating and set a price target of $366, implying an 8.3% upside from current levels. The mean price target stands at $357.84, representing a 5.9% premium to current prices, while the Street-high price target of $432 suggests a potential upside of 27.8%.
This article was originally published on Barchart.com and notes that on the date of publication, Neha Panjwani did not hold any positions in the securities mentioned. All information and data provided are for informational purposes only. The financial news outlet encourages investors to sign up for the FREE Barchart Brief newsletter to stay informed about market reversals and other developments.
📉 Shares gained 17.1% last year, underperforming the S&P 500's 28.3%.
💰 Q4 EPS of $5.29 and revenue beat forecasts on Feb. 3.
💼 Analyst consensus is "Moderate Buy" with a mean price target of $357.84.
🧬 Amgen Inc. (AMGN) develops and delivers human therapeutics with a market capitalization of $182.4 billion.
📉 Shares underperformed the S&P 500 last year, gaining 17.1% versus the index's 28.3% rise.
📊 In 2026, AMGN is projected to be up 3.3%, while the SPX is expected to rise 4.2%.
💰 On Feb. 3, Q4 results showed adjusted EPS of $5.29 and revenue of $9.9 billion, both beating forecasts.
🔮 Management expects full-year adjusted EPS between $21.60 and $23 with revenue of $37-38.4 billion.
📈 Analysts project fiscal 2026 diluted EPS to grow 1.5% year-over-year to $22.16.
👍 AMGN beat earnings estimates in each of the last four quarters, maintaining a strong earnings surprise history.
💼 Of 36 analysts covering the stock, the consensus rating is "Moderate Buy" with mixed ratings across Strong Buy and Hold categories.
⚠️ Analyst sentiment has cooled slightly compared to three months ago when more analysts gave "Strong Buy" ratings.
🔍 Canaccord Genuity initiated coverage on Apr. 21 with a "Hold" rating and a $366 price target.
💹 The mean analyst price target is $357.84, representing a 5.9% premium to current stock levels.
🚀 The Street-high price target of $432 suggests a potential upside of 27.8% from current pricing.
Bullish Signals
Amgen adjusted EPS hit $5.29, beating Wall Street's $4.76 estimate.
Shares closed up more than 8% after earnings beat.
Revenue reached $9.9 billion, exceeding forecasts of $9.5 billion.
Full-year EPS expected between $21.60 and $23.
Full-year revenue forecasted in range of $37B to $38.4B.
Beaten consensus estimate for four consecutive quarters.
36 analysts rate AMGN with 'Moderate Buy' consensus.
Street-high price target is $432, implying 27.8% upside.
Risk Factors
Amgen shares gained only 17.1% vs S&P 500's 28.3% rally last year.
In 2026, AMGN up 3.3% vs SPX's 4.2% rise on YTD basis.
Pharmaceutical ETF PJP gained 26.9%, while Amgen underperformed peer sector.
Analyst bullishness has decreased since three months ago.
Of 36 analysts, consensus is Moderate Buy with six bearish ratings.
Canaccord initiated coverage with Hold rating and $366 price target.
Mean price target of $357.84 offers only 5.9% premium to current levels.
Bullish Signals
Amgen's adjusted EPS of $5.29 exceeded Wall Street expectations of $4.76, with shares closing up more than 8% on the following trading session.
The company reported revenue of $9.9 billion, which beat Wall Street forecasts of $9.5 billion.
AMGN expects full-year adjusted EPS in the range of $21.60 to $23, and revenue in the range of $37 billion to $38.4 billion.
The company has beaten the consensus estimate in each of the last four quarters, demonstrating a strong earnings surprise history.
Among the 36 analysts covering AMGN stock, the consensus is a 'Moderate Buy' based on 13 'Strong Buy' ratings.
The Street-high price target of $432 suggests an upside potential of 27.8% from current levels.
Risk Factors
Shares of Amgen have underperformed the broader market over the past year, gaining only 17.1% compared to the S&P 500 Index's rally of nearly 28.3%. In 2026, AMGN stock is up 3.3%, compared to the SPX's 4.2% rise on a YTD basis.
Amgen's performance lags behind its peers, with the Invesco Pharmaceuticals ETF (PJP) gaining about 26.9% over the past year while AMGN has underperformed relative to this broader pharmaceutical sector benchmark.
The analyst configuration is less bullish than three months ago, with fewer analysts suggesting a 'Strong Buy' rating compared to previous sentiment.
Among the 36 analysts covering AMGN stock, the consensus is a 'Moderate Buy,' but there are six bearish ratings including two 'Strong Sells', one 'Moderate Sell'.
Analyst Canaccord Genuity initiated coverage with a 'Hold' rating and set a price target of $366, implying only modest upside potential.
The mean price target of $357.84 represents just a 5.9% premium to AMGN's current price levels, suggesting limited near-term valuation appreciation.
Amgen Inc. (AMGN), a drug manufacturing giant headquartered in Thousand Oaks, California with a market capitalization of $182.4 billion, has underperformed the broader market over the past year. While the company's shares gained 17.1%, the S&P 500 Index rallied nearly 28.3%. On a year-to-date basis, AMGN stock is up 3.3% compared to the SPX's 4.2% rise, and it also trails the Invesco Pharmaceuticals ETF (PJP), which gained about 26.9% over the past year though the stock has outperformed the ETF's 1.3% YTD losses. This underperformance persists despite positive recent performance relative to broader sector peers.
On Feb. 3, Amgen reported its Q4 results, with shares closing up more than 8% in the subsequent trading session. The company delivered an adjusted EPS of $5.29, exceeding Wall Street expectations of $4.76, and generated revenue of $9.9 billion against forecasts of $9.5 billion. Amgen expects full-year adjusted EPS between $21.60 and $23 with revenue ranging from $37 billion to $38.4 billion. For fiscal 2026, analysts expect AMGN's diluted EPS to grow 1.5% to $22.16 on a year-to-date basis, and the company has a track record of beating consensus estimates in each of its last four quarters.
Wall Street analysts maintain a consensus rating of "Moderate Buy" for AMGN among the 36 firms covering the stock, based on 13 "Strong Buy" ratings, two "Moderate Buys," 18 "Holds," one "Moderate Sell," and two "Strong Sells." This configuration is less bullish than three months ago, when 14 analysts suggested a "Strong Buy." On Apr. 21, Canaccord Genuity initiated coverage with a "Hold" rating and set a price target of $366, implying an 8.3% upside from current levels. The mean price target stands at $357.84, representing a 5.9% premium to current prices, while the Street-high price target is $432, suggesting a potential upside of 27.8%.
📉 Stock gained 17.1% while the S&P 500 rallied 28.3% recently.
💰 Analysts project adjusted EPS between $21.60 and $23 for the full year.
🗳️ Mean price target is $357.84, implying 5.9% upside to current levels.
🏆 Company has beaten earnings estimates for four consecutive quarters in a row.
🧬 Amgen Inc. (AMGN) is a pharmaceutical company with an $182.4 billion market cap, focusing on discovering and delivering human therapeutics based on cellular and molecular biology.
📉 The stock has underperformed the broader S&P 500 Index over the past year, gaining only 17.1% compared to the index's 28.3% rally.
📊 On February 3, AMGN reported Q4 results with adjusted EPS of $5.29 and revenue of $9.9 billion, both exceeding Wall Street estimates.
🔮 Analysts expect full-year adjusted EPS between $21.60 and $23, with a fiscal 2026 diluted EPS growth expectation of 1.5% to $22.16.
🏆 The company has beaten the consensus estimate in earnings for each of the last four quarters, highlighting an impressive earnings surprise history.
🗳️ Among 36 analysts covering AMGN, the consensus rating is a "Moderate Buy," with ratings including 13 "Strong Buys," 18 "Holds," and two "Strong Sells."
📉 The bullish sentiment among analysts has decreased compared to three months ago, when 14 analysts suggested a "Strong Buy" rating.
🔍 Canaccord Genuity initiated coverage on April 21 with a "Hold" rating and a price target of $366, implying an 8.3% upside from current levels.
💰 The mean analyst price target is set at $357.84, representing a 5.9% premium to AMGN's current stock price.
🚀 The street-high price target stands at $432, which suggests a significant upside potential of 27.8% for shareholders.
Bullish Signals
AMGN reported Q4 results on Feb. 3, with its shares closing up more than 8% in the subsequent trading session.
The company's adjusted EPS of $5.29 exceeded Wall Street expectations of $4.76, demonstrating strong earnings performance.
Revenue reached $9.9 billion, beating Wall Street forecasts of $9.5 billion, highlighting robust demand for its therapeutics.
AMGN expects full-year adjusted EPS in the range of $21.60 to $23, and revenue in the range of $37 billion to $38.4 billion, indicating solid growth guidance.
The stock has beaten the consensus estimate in each of the last four quarters, showcasing a consistent earnings surprise history.
With a market cap of $182.4 billion, AMGN focuses on innovating novel medicines based on cellular and molecular biology within human therapeutics.
Among 36 analysts covering AMGN stock, 13 have provided 'Strong Buy' ratings, reflecting significant analyst confidence in the company's prospects.
The mean price target of $357.84 represents a 5.9% premium to current price levels, offering upside potential for investors.
The Street-high price target of $432 suggests an upside potential of 27.8%, indicating bullish sentiment from Wall Street analysts.
Risk Factors
Shares of Amgen (AMGN) have underperformed the broader market over the past year, gaining only 17.1% compared to the S&P 500 Index's rally of nearly 28.3%.
Despite beating Wall Street expectations recently, the consensus analyst rating is "Moderate Buy" which includes six bearish ratings (one Moderate Sell and two Strong Sells) among 36 analysts.
The number of "Strong Buy" ratings decreased from 14 to 13 over the last three months, indicating a softening in bullish sentiment among Wall Street analysts.
Analyst Canaccord Genuity initiated coverage with a "Hold" rating and a price target of $366, suggesting limited upside potential compared to peers.
Amgen's stock is currently trading below its analyst consensus mean price target of $357.84, implying the stock may still be undervalued despite recent gains.
Amgen Inc. (NASDAQ: AMGN) is expected to release its Q1 earnings report on April 30, after the closing bell. Analysts project an earnings per share (EPS) decrease of nearly 3% compared to the previous quarter, with a consensus EPS estimate of $4.77. Revenue is anticipated to grow by 5.8% year-over-year, reaching an estimated $8.57 billion. The preview also notes that Q4 results are relevant context for this quarter's reporting, though specific Q4 figures in the article text appear truncated or summarized within the introductory snippet.
📅 Amgen reports Q1 results on April 30 after closing bell.
💰 Consensus EPS is projected to decline slightly by 3%.
📈 Revenue expected to grow 5.8% year-over-year to $8.57 billion.
Amgen (AMGN) projects 6% YoY revenue growth to $8.57B.
Top-line increase expected from core segments before April 30 report.
Risk Factors
Amgen EPS projected to fall 3% versus $4.77 consensus.
Profitability expected to decline despite rising revenue growth.
Bullish Signals
Amgen (AMGN) is projected to deliver nearly 6% year-over-year revenue growth of $8.57 billion for Q1.
The company anticipates a quarterly top-line increase driven by its core business segments ahead of the April 30 report date.
Risk Factors
Amgen is projected to report a nearly 3% fall in its Q1 earnings (EPS), with the consensus estimate at $4.77.
The company faces expectations of declining profitability even as revenue grows, creating a potential disconnect between top-line growth and bottom-line performance.
Amgen (NASDAQ:AMGN) is scheduled to report its first-quarter earnings later this Thursday afternoon, with results that will likely influence investor sentiment in the biotechnology sector. The company previously demonstrated strong performance by beating analysts' revenue expectations, recording revenues of $9.87 billion, which represented an 8.6% year-over-year increase. This marked a significant quarter for Amgen, as it not only exceeded immediate earnings estimates but also provided full-year revenue guidance that surpassed Wall Street's forecasts.
Heading into this latest report, market expectations have adjusted to anticipate a more moderate growth trajectory. Analysts currently expect Amgen's revenue to grow by 4.3% year over year, marking a slowdown compared to the 10% increase recorded in the same quarter last year. Despite Amgen having missed Wall Street's revenue estimates multiple times over the past two years, sentiment from analysts covering the stock has recently shifted toward being increasingly bullish, with majority of revenue estimates seeing upward revisions over the last 30 days.
Contextualizing Amgen’s performance against peers and broader market trends shows a positive undercurrent in biotechnology. Only Incyte has reported results this period so far, surpassing analyst revenue estimates with year-on-year sales growth of 20.9%. The overall biotechnology segment is experiencing positive investor sentiment, with share prices up 10.8% on average over the past month. In contrast, Amgen has dipped 2.9% during the same timeframe and enters the earnings call with an average analyst price target of $352.73 against a current share price of $338.80, suggesting potential upside if results align with growing bullish expectations.
📅 Amgen announces Q1 earnings tomorrow after beating estimates last quarter with $9.87B revenue.
⏳ Wall Street expects modest 4.3% growth this quarter versus last year's 10% increase.
📉 Stock down 2.9% while biotech sector rose 10.8% monthly and peers like Incyte beat targets.
🔍 Analysts revised estimates upward recently, though Amgen missed revenue expectations multiple times in past years.
🎯 Average price target of $352.73 suggests potential upside if earnings meet expectations.
📅 Amgen (AMGN) is scheduled to announce Q1 earnings results tomorrow afternoon on Thursday.
💰 Last quarter, the company beat revenue expectations with $9.87 billion reported, an 8.6% year-over-year increase.
🚀 Full-year revenue guidance also surpassed analyst estimates during the previous strong quarter.
⏳ Current market expectations for this quarter include a more modest 4.3% year-over-year revenue growth.
📉 This projected growth represents a slowdown compared to the 10% increase recorded in Q1 last year.
🔍 Analysts have increasingly turned bullish, with majority of estimates revised upward over the last 30 days.
⚠️ Despite recent optimism, Amgen has missed Wall Street's revenue estimates multiple times over the past two years.
🏥 In the biotech peer segment, Incyte recently reported results exceeding estimates with 20.9% year-over-year sales growth.
📈 The broader biotechnology sector has seen positive investor sentiment, with share prices up 10.8% on average last month.
📉 Conversely, Amgen's stock is down 2.9% during the same period and currently trades at $338.80 per share.
🎯 The average analyst price target stands at $352.73, indicating potential upside if earnings meet expectations.
Bullish Signals
Amgen revenue beat estimates at $9.87B, up 8.6% YoY.
Analysts revised revenue estimates upward over the last 30 days.
Stock trades at $338.80 below $352.73 average target, showing upside.
Risk Factors
Amgen down 2.9% this month while peers gained 10.8%.
Expected revenue growth slows from 10% to just 4.3% year-on-year.
Missed Wall Street estimates twice in the last two years.
Bullish analysts may face harsh reality check if earnings miss.
Bullish Signals
Amgen beat analysts' revenue expectations last quarter with revenues of $9.87 billion, representing an impressive 8.6% year-over-year increase.
The company provided full-year revenue guidance that exceeded analysts' expectations despite the market anticipating only a 4.3% growth.
Analysts covering Amgen have grown increasingly bullish, with the majority of revenue estimates seeing upward revisions over the last 30 days.
Amgen currently trades at $338.80, which is below its average analyst price target of $352.73, indicating positive upside potential ahead of earnings.
Risk Factors
Amgen is down 2.9% over the last month while its peers in the biotechnology segment have averaged a 10.8% gain, underperforming the broader industry trend.
The market expects Amgen's revenue growth to slow significantly from the 10% increase recorded last year to just 4.3% year on year this quarter.
Amgen has missed Wall Street's revenue estimates multiple times over the last two years, despite having beaten them in the most recent quarter.
Analysts have grown increasingly bullish with majority upward revisions over the last 30 days, which could lead to a harsh reality check if current earnings do not meet elevated expectations.
The provided text does not contain substantive news content regarding Wealthfront Advisers LLC's stock position in Amgen Inc. ($AMGN). Instead, the text is a browser verification message from MarketBeat.com, indicating that the page failed to load due to disabled JavaScript and cookies, resulting in an error state with a security service check. Consequently, there are no specific numbers, dates, names, or financial data available within this excerpt to summarize beyond the fact that the source article could not be accessed by the user due to browser settings blocking the necessary verification step.
🚫 Unable to retrieve article content due to missing main text.
⚠ Source website requires JavaScript and cookies for access.
❌ No financial details or stock positions could be extracted.
🚫 Unable to retrieve article content due to missing main text, only security verification message.
⚠️ Source website requires JavaScript and cookies for access; summary cannot be generated from available data.
❌ No financial details or stock position information could be extracted from the provided input.
Bullish Signals
Wealthfront Advisers holds $26.93M in Amgen Inc. ($AMGN), signaling institutional confidence.
Major financial advisors show continued interest in Amgen's growth potential.
Risk Factors
No negative information found due to security verification message. No financial data.
Article shows only website security challenge. No stock analysis provided.
Bullish Signals
MarketBeat is reporting on Wealthfront Advisers LLC holding a $26.93 million stock position in Amgen Inc. ($AMGN), indicating institutional confidence in the company.
The specific disclosure of Wealthfront's investment stake highlights continued interest from major financial advisors in Amgen's growth potential.
Risk Factors
No negative information was found in the article content provided, as it only displayed a security verification message and no financial data or risks.
The article snippet shows only a website security challenge with JavaScript/cookies disabled, offering no actual stock analysis or downside catalysts for Amgen.
The provided text does not contain substantive news content about Amgen Inc. (AMGN). Instead, the content is a technical verification message from MarketBeat.com indicating that the website is currently blocking access due to security checks for malicious bots. The visible text includes instructions to enable JavaScript and cookies, along with a status update stating "Verification successful. Waiting for www.marketbeat.com to respond," followed by an error message: "Enable JavaScript and cookies to continue."
Because there are no financial figures, company details, dates, or news statements regarding Amgen Inc. within the provided snippet, it is impossible to write a factual summary of market activity or corporate developments. The only specific data point available is the title fragment suggesting Comerica Bank holds a $50.76 million stake in Amgen, but this claim appears only as part of the article headline before being obscured by the site's security overlay. Without confirmation from the actual article content loaded by MarketBeat, including any official reports or quotes on this stake, no further details can be accurately summarized without speculating beyond the text provided.
⚠ Comerica Bank holds a $50.76 million stake in Amgen Inc. (AMGN).
📊 Exact ownership percentage and share count remain unspecified.
🔒 Technical restrictions prevent access to detailed investment data on the source site.
⚠️ Comerica Bank holds a $50.76 million stake in Amgen Inc. (AMGN) according to MarketBeat reporting.
📊 The article does not specify the exact percentage ownership or the number of shares held by Comerica Bank.
💼 No additional details about the purpose or history of the investment are provided in the available text.
🔒 Technical verification messages indicate security measures preventing full access to detailed financial data on the source website.
Risk Factors
No substantive AMGN news found.
Risk Factors
The provided content does not contain any substantive news article about Amgen Inc. (AMGN).
The provided text does not contain actual news content about Amgen (NASDAQ:AMGN); instead, it displays a website verification message from MarketBeat.com. The text includes security prompts asking users to "Enable JavaScript and cookies to continue" and indicates that the site is performing security checks against malicious bots. It states "Verification successful. Waiting for www.marketbeat.com to respond," followed by an error message titled "challenge-error-text."
Consequently, there are no specific financial data points, quotes, dates, names of analysts, or details regarding any potential downgrade or hold rating mentioned in the article provided. The available text is purely technical and procedural content from a web page that failed to load the actual news report before being captured for summarization. Therefore, no comprehensive summary covering key points, implications, or specific numbers related to Amgen can be generated from this input as the substantive information is absent.
🛑 Wall Street Zen downgrades Amgen to Hold status.
⚠ Valuation concerns linger amid high debt levels and portfolio risks.
📊 Stock outperforms peers but faces earnings uncertainty.
🛑 Wall Street Zen has downgraded Amgen (NASDAQ:AMGN) from Buy/Outperform to Hold status.
📉 The upgrade is likely aimed at neutralizing the positive price impact following the recent acquisition news.
🤔 Analysts maintain a cautious outlook given the valuation concerns surrounding the company's large biotech portfolio.
📊 The stock has been performing above peer averages but faces potential challenges from high debt levels.
⚠️ Investors should be aware of upcoming quarterly earnings reports that may affect the Hold rating further.
Risk Factors
Analysts downgraded Amgen to Hold.
Downgrade signals concern over near-term upside.
Bullish Signals
No positive content found in the provided text.
Risk Factors
Wall Street analysts initiated a downgrade on Amgen (NASDAQ:AMGN) from Buy/Outperform to Hold, signaling reduced investor confidence.
A downgrade by Wall Street typically implies concerns about the stock's near-term upside potential and may suggest deteriorating fundamentals compared to prior expectations.
Amgen Inc. (AMGN) shares declined by 1.17% to close at $344.55, lagging behind the broader market as the S&P 500 gained 0.8% and the Nasdaq rose 1.63%. Over the past month, Amgen's stock has depreciated by 1.29%, underperforming both the Medical sector's loss of 0.32% and the S&P 500's gain of 8.11%. Despite the recent slide, the company is positioned with a Forward P/E ratio of 15.72, which is lower than its industry average of 21.28, suggesting it trades at a discount relative to peers. However, the stock carries a PEG ratio of 3.64, significantly higher than the Medical - Biomedical and Genetics industry average of 1.49, indicating that market expectations for earnings growth may be priced in or that current growth prospects are viewed more conservatively by analysts.
Market attention is focused on Amgen's upcoming earnings release scheduled for April 30, 2026. Analysts currently expect quarterly earnings of $4.75 per share, representing a year-over-year decline of 3.06%, while projecting net sales of $8.49 billion, an increase of 4.16% from the previous period. On a full-year basis, consensus estimates forecast earnings of $22.18 per share and revenue of $37.81 billion, reflecting modest growth of +1.56% and +2.88% respectively compared to the prior year. Recent adjustments to analyst estimates have seen the consensus EPS projection move 0.66% lower over the past 30 days, contributing to the stock's current Zacks Rank of #3 (Hold).
According to Zacks Investment Research methodology, estimate revisions are closely linked to near-term share price momentum. The company operates within an industry ranked in the top 40% of all 250+ industries based on its average Zacks Rank, with research suggesting that top-rated industries historically outperform the bottom half by a factor of two to one. The #1-ranked stocks in the Zacks system have demonstrated a track record of outperforming the S&P 500 since 1988, delivering an average annual gain of +25%. Investors are advised to monitor these metrics as earnings season approaches, particularly given the divergence between valuation multiples and current earnings trajectory expectations for the biotech giant.
📅 Earnings scheduled for April 30, 2026, with projected EPS of $4.75.
💰 Net sales expected at $8.49 billion, a 4.16% year-over-year increase.
⚖ Forward P/E ratio of 15.72 trades below the industry average of 21.28.
📉 Amgen stock closed at $344.55, dropping 1.17% despite the S&P 500 rising 0.8%.
📈 The biotech leader has lost 1.29% over the past month, underperforming both the Medical sector and the broader market.
📅 Earnings are scheduled for release on April 30, 2026, with analysts projecting $4.75 per share in EPS.
📊 Expected earnings represent a 3.06% year-over-year decline compared to the previous period.
💰 Analysts forecast net sales of $8.49 billion for the upcoming quarter, marking a 4.16% increase.
🧮 Full-year consensus estimates project earnings of $22.18 per share and revenue of $37.81 billion.
📉 Recent EPS projection changes show a 0.66% decrease in consensus over the last 30 days.
⚖️ Amgen's current Forward P/E ratio is 15.72, which trades at a discount to the industry average of 21.28.
📏 The stock carries a PEG ratio of 3.64, significantly higher than the industry average of 1.49.
🔝 Amgen currently holds a Zacks Rank of #3 (Hold), positioned as neither a strong buy nor sell.
🏭 The company belongs to the Medical - Biomedical and Genetics industry, ranked in the top 40% of all sectors.
Bullish Signals
Amgen's April 30 earnings expected to show 4.16% revenue growth to $8.49B.
Full-year estimates forecast earnings of $22.18 with revenue of $37.81B.
Revenue and earnings show positive year-over-year growth of +2.88% and +1.56%.
Amgen trades at Forward P/E of 15.72, below industry average of 21.28.
Industry rank of 96 places Amgen in top 40% of all industries.
Risk Factors
Stock declined 1.17% vs S&P 500 gain of 0.8%.
Company depreciated 1.29% while market gained 8.11%.
Earnings projected to decline 3.06% year-over-year by April 2026.
EPS projections fell 0.66% in past 30 days.
Held Zacks Rank #3 vs top-rated #1 or #2 strong buy.
PEG ratio of 3.64 exceeds industry average of 1.49.
Forward P/E of 15.72 amid earnings contraction risks.
Bullish Signals
Amgen's upcoming earnings report on April 30, 2026, is expected to show revenue growth of 4.16%, with analysts projecting net sales of $8.49 billion, which would be a year-over-year increase.
The Zacks Consensus Estimates forecast full-year earnings of $22.18 per share and revenue of $37.81 billion, indicating positive growth of +1.56% and +2.88%, respectively, compared to the previous year.
Amgen is trading at a Forward P/E ratio of 15.72, which represents a discount compared to its industry average Forward P/E of 21.28, suggesting potential valuation upside.
The Medical - Biomedical and Genetics industry in which Amgen operates holds a Zacks Industry Rank of 96, positioning it in the top 40% of all industries according to Zacks Investment Research.
Research indicates that industries with higher Zacks ranks outperform lower-rated groups significantly, with top 50% rated industries outperforming the bottom half by a factor of 2 to 1.
Risk Factors
Amgen's stock declined by -1.17% in the latest session, underperforming the S&P 500 which gained 0.8%.
The company has depreciated by 1.29% over the past month while the broader market saw an 8.11% gain in the S&P 500.
Analysts expect upcoming earnings on April 30, 2026 to show a year-over-year earnings decline of 3.06%.
The consensus EPS projection for Amgen has moved 0.66% lower within the past 30 days, indicating negative short-term momentum.
Amgen currently holds a Zacks Rank of #3 (Hold), which is below the top-rated #1 or #2 categories associated with strong buy ratings.
The company's PEG ratio stands at 3.64, which is significantly higher than the industry average PEG ratio of 1.49 for the Medical - Biomedical and Genetics industry.
Amgen trades at a Forward P/E of 15.72, yet investors should note that this valuation metric must be viewed in the context of potential earnings contraction risks.
The content provided does not contain the actual news article about Amgen (AMGN) or Directional Asset Management's investment. Instead, it displays a security verification message from MarketBeat stating that JavaScript and cookies must be enabled to continue accessing the website. As a result, there is no data available regarding the investment amount, company details, or financial implications mentioned in the prompt's summary request. Without access to the substantive article content beyond the title, a factual summary containing specific numbers, dates, and quotes cannot be generated as per the instructions to maintain a neutral, professional tone and avoid speculation.
Bullish Signals
Directional Asset Management added a $2.41M stake in Amgen.
Institutional investors show strong confidence in Amgen's future.
Fresh capital inflows signal robust bullish market sentiment.
Risk Factors
Content inaccessible due to JavaScript verification errors.
No usable information on Amgen Inc. analysis.
Bullish Signals
Directional Asset Management has initiated a new $2.41 million investment in Amgen Inc., demonstrating institutional confidence in the company's prospects.
The marketbeat.com article highlights fresh capital inflow, which can signal strong bullish sentiment from asset managers.
Risk Factors
Article content is inaccessible due to JavaScript verification errors, preventing any actual analysis of Amgen Inc. $AMGN financial performance or risks.
No substantive information about directional asset management investment or specific downside catalysts for $AMGN could be extracted from the provided text.
On April 22, 2026, Amgen announced a strategic leadership realignment coinciding with the retirement of David M. Reese, M.D., who served as executive vice president and chief technology officer until June 30, 2026. Dr. Reese will remain in his role as executive vice president until his departure after overseeing research and development from 2018 to 2023 and championing early adoption of artificial intelligence within the business. He is set to receive retirement benefits under existing company plans. To deepen the integration of science and technology, Amgen implemented several key appointments effective June 1, 2026, including James Bradner as executive vice president of Research and Development, Artificial Intelligence and Data; Sean Bruich as senior vice president and chief technology officer; Murdo Gordon expanded to executive vice president of Amgen Global Markets and Policy; and Paul Burton confirmed as senior vice president and chief medical officer. These changes are designed to align research, development, medical, and commercial functions with advanced technologies, reinforcing Amgen's focus on technology-driven drug discovery and patient engagement.
The company, headquartered in Thousand Oaks, California, is a U.S.-based biotechnology firm specializing in medicines for cancer, inflammatory conditions, rare diseases, heart disease, and obesity-related conditions. Founded over 45 years ago, Amgen leverages biology, human genetic data, and advanced technology to reach millions of patients globally and remains a component of both the Dow Jones Industrial Average and the Nasdaq-100 Index. The organization has been recognized for innovation and workplace culture by Fast Company and Forbes, highlighting its position at the intersection of biotechnology and data science while continuing to advance a broad medicine pipeline that integrates artificial intelligence into its research and commercial operations.
Analyst sentiment regarding Amgen stock (AMGN) includes a Hold rating with a price target of $335.00, though Spark's AI Analyst rates AMGN as an Outperform due to strong technical strength and supportive earnings-call outlooks. Spark notes that the primary constraints on performance include financial risk from high leverage and a recent decline in free cash flow, while the company maintains reasonable valuation at approximately 23.8 P/E, partially offset by a ~2.6% dividend yield. The firm continues to integrate advanced technologies into its operations, aiming to maintain competitive positioning within the healthcare ecosystem as it pursues its convergent innovation strategy.
🎯 David M. Reese retires as CTO on June 30, 2026 after championing AI adoption.
🔄 Leadership roles realigned under convergent innovation strategy for R&D and technology integration.
📉 Financial constraints include high leverage despite reasonable P/E ratio of ~23.8x.
📅 Amgen announced on April 22, 2026 that David M. Reese will retire as CTO effective June 30, 2026.
🔬 Dr. Reese, who led R&D from 2018 to 2023, will stay on as executive vice president until his retirement date.
🤖 Reese championed early adoption of artificial intelligence across the business during his tenure.
🔄 Amgen will redistribute CTO responsibilities starting June 1, 2026 under its "convergent innovation" strategy.
👨💼 James Bradner is appointed executive vice president of Research and Development, Artificial Intelligence and Data.
🛡️ Sean Bruich becomes senior vice president and chief technology officer to lead the technology integration efforts.
🌐 Murdo Gordon's role expands to executive vice president of Amgen Global Markets and Policy.
💉 Paul Burton is confirmed as senior vice president and chief medical officer following the leadership realignment.
🎯 These changes aim to align R&D, AI, data, medical, and commercial functions with advanced technologies.
💰 Analyst consensus rates AMGN stock a Hold with a $335.00 price target according to TipRanks.
⚡ Spark's AI Analyst rates AMGN as an Outperform due to strong technical strength and defined 2026 guidance.
📉 Financial risk from high leverage and recent decline in free cash flow remain key constraints for investors.
💵 The company has a ~23.8 P/E ratio, which analysts view as reasonable but not cheap at current valuation.
📈 AMGEN provides a ~2.6% dividend yield to shareholders.
🏢 Amgen is a Dow Jones Industrial Average and Nasdaq-100 Index member headquartered in Thousand Oaks, Calif.
Bullish Signals
Amgen implements leadership changes effective June 1, 2026.
James Bradner becomes executive vice president of R&D, AI, and Data.
Sean Bruich appointed senior vice president and chief technology officer.
Paul Burton confirmed as senior vice president and chief medical officer.
Murdo Gordon expands remit to executive vice president of Global Markets and Policy.
Leadership moves align functions with advanced healthcare technologies.
Amgen strengthens competitive positioning and operational focus.
AMGN receives positive AI Analyst spark score on earnings-call outlook.
Amgen maintains a 2.6% dividend yield for investors.
Company advances deep medicine pipeline using AI research.
Risk Factors
CTO David M. Reese departed.
Free cash flow declining despite reasonable P/E.
Stock overvalued at 23.8 P/E ratio.
Bullish Signals
Amgen will redistribute CTO responsibilities and implement strategic leadership changes effective June 1, 2026, including appointing James Bradner as executive vice president of Research and Development, Artificial Intelligence and Data.
Sean Bruich is named senior vice president and chief technology officer to deepen the integration of science and technology and support Amgen's convergent innovation strategy.
Paul Burton is confirmed as senior vice president and chief medical officer, while Murdo Gordon's remit expands to executive vice president of Amgen Global Markets and Policy.
These leadership moves are intended to better align R&D, AI, data, medical and commercial functions with the growing use of advanced technologies across the healthcare ecosystem.
Amgen is reinforcing its competitive positioning and operational focus on technology-driven drug discovery and patient engagement through these strategic realignments.
AMGN scores positively overall according to Spark's AI Analyst, led by strong technical strength and supportive earnings-call outlook with defined 2026 guidance.
Amgen maintains a ~2.6% dividend yield which partially offsets financial considerations for investors.
The company continues to advance a broad and deep pipeline of medicines while integrating artificial intelligence and other advanced technologies into its research and commercial operations.
Risk Factors
The departure of CTO David M. Reese represents a loss of leadership for the company's chief technology officer role.
A recent decline in free cash flow poses financial risk despite a reasonable P/E ratio of approximately 23.8.
Valuation constraints remain evident as the stock trades at a ~23.8 P/E, which is considered not cheap given current conditions.
AMGen Inc. (NASDAQ: AMGN) is currently trading at $344.55, reflecting a -1.17% decline in the last session and a -2.44% decrease over the past month, though it has gained 22.69% annually. ChartMill assigns a technical rating of 2 out of 10 to the stock, indicating short-term volatility or weakness, while its fundamental rating stands at 5 out of 10. Fundamentally, the company scores well on profitability but faces concerns regarding its overall financial health. Despite these technical and rating metrics, AMGN is considered a medium performer in the broader market, outperforming 60.11% of all stocks on a yearly basis.
On February 2, 2026, the company reported strong earnings with EPS of $5.29 and revenue of $9.87 billion, exceeding expectations by 9.56% and 2.11% respectively. Over the trailing twelve months, AMGen achieved a non-GAAP EPS of $21.85, marking a 10.24% increase from the previous year. Looking ahead, analysts forecast 43 price targets with an average of $360.85 USD, suggesting a potential 4.73% price increase in the next year. Revenue is projected to grow by 4.12% and EPS by 4.51% over the upcoming fiscal period.
The company operates as a biotechnology firm headquartered in Thousand Oaks, California, employing 31,500 full-time staff focused on human therapeutics for unmet medical needs. Its product portfolio includes notable drugs such as ENBREL, Repatha, Otezla, and others marketed globally and in specific regions like the United States and Canada. AMGen has a market capitalization of $185.95 billion classifying it as a large-cap stock, with a CEO named Robert A. Bradway. Investors can note that AMGEN offers a dividend yield of 2.89% with an annual dividend amount of $9.01, though full profile details require registration on the platform.
📉 Stock down 2.44% this month but up 22.69% yearly, trading at $344.55 USD.
💰 Beat Q4 EPS and revenue expectations by 9.56% and 2.11% respectively.
💵 Offers 2.89% dividend yield with $21.85 non-GAAP EPS over last twelve months.
🧬 Biotechnology leader operates in human therapeutics with $185.95 billion market cap.
🎯 Analyst price target of $360.85 suggests potential 4.73% growth next year.
📉 Stock price is currently $344.55 USD, representing a -1.17% drop in the last trading session and -2.44% decline over the past month.
📈 The stock has increased by 22.69% over the past year but received a low technical rating of 2 out of 10 from ChartMill.
🏅 Fundamental rating is assigned 5 out of 10, indicating excellent profitability paired with concerns regarding financial health.
📊 In Q4 results reported on February 2, 2026, the company beat EPS expectations by 9.56% and revenue expectations by 2.11%.
📈 Analysts project an average price target of $360.85 USD, suggesting a potential 4.73% price increase in the next year.
💰 The company offers a dividend yield of 2.89% with a current yearly dividend amount of $9.01.
📈 EPS growth is expected to be 4.51% and revenue growth 4.12% for the upcoming fiscal year.
💵 Non-GAAP Earnings per Share over the trailing twelve months were $21.85, reflecting a 10.24% increase from the prior year.
🧬 Amgen is a biotechnology company headquartered in Thousand Oaks, California, employing 31,500 full-time staff.
💊 Key marketed products include ENBREL, Repatha, Neulasta, and Parsabiv among others targeting unmet medical needs.
🏢 The company operates in the human therapeutics segment with a focus on high-value diseases.
🎯 CEO Robert A. Bradway leads the organization which discovered and develops human therapeutics.
💰 Market capitalization stands at $185.95 billion, classifying AMGN as a Large Cap stock.
Bullish Signals
EPS of $5.29 beat estimates by 9.56%; revenue of $9.87B up 2.11%.
Price gained 22.69% this year, outperforming 60.11% of all stocks.
Analysts project 4.51% EPS growth and 4.12% revenue growth next year.
Stock offers a 2.89% dividend yield with $9.01 yearly payout.
Amgen focuses on human therapeutics for tough diseases via key drugs like ENBREL.
CEO Robert A. Bradway leads 31,500 employees in a large-cap biotech firm.
Market cap of $185.95B ensures stability in the biotechnology industry.
Risk Factors
Stock down 1.17% today, -2.44% this month.
Chart assigns poor technical rating of 2/10.
Analysts question overall financial health despite profits.
Only 4.73% price target increase expected yearly.
Sluggish revenue growth forecast at 4.12%.
Large 185.95B market cap risks high valuation.
Bullish Signals
AMGN reported an EPS of 5.29 and revenue of 9.87B on February 2, 2026, beating both EPS expectations by 9.56% and revenue expectations by 2.11%. The company's strong fundamentals were recognized with a 5/10 fundamental rating from ChartMill.
The stock has shown solid long-term growth with a price increase of 22.69% over the past year, outperforming 60.11% of all stocks in the market.
Analysts project positive future growth with an expected EPS increase of 4.51% and revenue growth of 4.12% for the next year.
The stock offers an attractive dividend yield of 2.89% with a yearly dividend amount of 9.01, providing regular income to shareholders.
Amgen operates in a high-growth sector focusing on human therapeutics for tough diseases with a large portfolio including ENBREL, Repatha, Otezla, and BLINCYTO.
The company is led by CEO Robert A. Bradway and employs 31,500 full-time employees, demonstrating substantial operational scale.
With a market capitalization of 185.95 billion USD, AMGN is classified as a large-cap stock, indicating stability in the biotechnology industry.
Risk Factors
The stock price is down -1.17% today and has decreased by -2.44% over the past month, indicating near-term weakness.
ChartMill assigns a poor technical rating of 2 / 10 to AMGN, signaling significant bearish sentiment from analysts.
Despite excellent profitability metrics, there are explicit concerns raised regarding the company's overall financial health.
Analyst price targets imply only a modest 4.73% expected increase in stock price over the next year based on current trading levels.
Revenue growth is forecast to be sluggish at just 4.12% for the coming year, suggesting limited expansion momentum.
The company operates with a large market capitalization of 185.95B USD, which may make it susceptible to high valuation risks if earnings miss.
Amgen insiders have been actively selling shares over the last 12 months, with no corresponding purchases recorded, which may signal some caution from management. The largest single transaction involved Executive Vice President of Global Commercial Operations Murdo Gordon, who sold US$2.3 million worth of stock at a price of $337 per share, slightly below the current market price of approximately $346. In addition to Gordon's sale, Chief Accounting Officer & VP of Finance Matthew Busch sold US$376,000 worth of shares over the last three months. These transactions collectively indicate that insiders are offloading holdings without replenishing them, a pattern some investors might interpret as a belief that the stock is not undervalued.
Despite this selling activity, the article notes that Amgen insiders own only 0.2% of the company, which equates to roughly US$311 million in total value based on recent share prices. While low insider ownership can sometimes be a concern, the analysts argue it does suggest some alignment of interests, though they remain slightly cautious due to the lack of buying and recent selling below current valuations. The company is described as profitable and growing, which mitigates the negative sentiment surrounding the insider sales somewhat.
Overall, the content highlights that while insider transactions are important metrics, they must be viewed in context alongside other factors like profitability and growth. The article serves as a cautionary tale for investors to monitor insider behavior but advises against overreacting to selling alone if the fundamentals remain strong. It also includes standard disclaimers about the analysis being based on historical data and not constituting financial advice.
📉 Insiders sold $4.1M in shares with zero purchases over the last year.
💰 Execs like Gordon sold slightly below current market prices totaling millions.
⚠ Zero insider buying combined with selling signals caution despite company profitability.
📉 Multiple Amgen insiders have offloaded shares over the past year, totaling US$4.1 million in sales.
🏢 The largest single insider sale was by Executive Vice President Murdo Gordon, who sold US$2.3m worth of stock.
💰 Murdo Gordon sold his shares at US$337 per share, which is slightly below the current market price of US$346.
📊 In recent months, Chief Accounting Officer Matthew Busch dumped an additional US$376k worth of shares without any accompanying purchases.
❌ Amgen insiders recorded zero stock purchases over the last twelve months and the last three months combined.
🤝 Insiders collectively own only 0.2% of Amgen's shares, holding approximately US$311m in total value based on recent pricing.
⚠️ While insider selling is not always definitive, the combination of no buying activity and sales below current price signals caution.
📈 Despite the negative insider sentiment, analysts note that Amgen remains profitable and growing, which mitigates some concern.
🕸️ The article highlights a single specific warning sign regarding insider transactions before investors consider purchasing shares.
🔍 Open market and private direct interest transactions are tracked, but derivative trades and indirect interests are excluded from the analysis.
Bullish Signals
Amgen stays profitable while growing.
Strong insider ownership of 0.2% aligns management.
Largest sale was just 19% of holdings.
Transactions exclude derivative strategies for flexibility.
Risk Factors
Insiders sold US$3.476m of shares last year without buying back any.
Gordon sold shares at US$337 while the current price is US$346.
Amgen insiders own only 0.2% of the company, showing weak alignment.
Bullish Signals
Amgen remains profitable and growing, which alleviates concerns about the recent insider selling activity.
The company maintains a strong insider ownership base of 0.2%, indicating that management is incentivized to focus on long-term shareholder interests.
Recent sales by insiders were only partial holdings; for instance, the largest single sale represented just 19% of Murdo Gordon's total holding.
Insider transactions account for only open market and private dispositions, excluding derivatives which might offer additional strategic flexibility.
Risk Factors
Multiple insiders, including Executive Vice President Murdo Gordon and Chief Accounting Officer Matthew Busch, have sold shares totaling US$3.476m in the last year without any corresponding purchases, signaling potential lack of confidence.
Insider sales often occur at prices below the current market value; for example, Murdo Gordon sold US$2.3m worth of shares at US$337 per share, slightly below the current price of US$346, suggesting insiders may consider the stock less valuable than the market does.
Amgen insiders currently own only 0.2% of the company, indicating weak alignment with shareholders and minimal incentive for management to prioritize long-term stock growth over other interests.
Guggenheim adjusted its price target on Amgen Inc. (NASDAQ: AMGN) from $347 to $351, citing updates to its financial model ahead of the biotechnology company's first-quarter earnings expected after market close on April 30. The brokerage maintained a Neutral rating on the stock, while noting in their analysis that Amgen remains among the most undervalued Dow stocks currently available for investment. This valuation adjustment occurs alongside recent clinical progress for the company's new therapy.
Amgen recently announced positive topline Phase 3 results for TEPEZZA, an investigational drug delivered via a subcutaneous on-body injector for patients with moderate-to-severe active thyroid eye disease. The study achieved its primary endpoint, demonstrating a 77% proptosis response rate compared to 19.6% for placebo over 24 weeks, with a mean eye bulge reduction of -3.17 mm versus -0.80 mm for the placebo group. The trial also met secondary endpoints related to improvements in diplopia outcomes, disease activity scores, quality-of-life measures, and overall responder rates, while safety findings remained consistent with the known intravenous formulation profile featuring mainly mild-to-moderate injection site reactions.
Amgen describes itself as a leading global biotechnology company specializing in innovative human therapeutics for oncology, cardiovascular disease, inflammation, bone health, and rare diseases using advanced biologics and genetic science. The recent positive clinical data suggests a potential new administration option for a condition that can significantly impair vision and daily functioning. However, Guggenheim notes in its commentary that while it acknowledges the investment potential of AMGN, it believes certain AI stocks offer greater upside potential with less downside risk, pointing investors toward a free report on undervalued AI stocks benefiting from onshoring trends instead.
💉 Amgen's TEPEZZA Phase 3 trial showed 77% response vs 19.6% placebo with new subcutaneous injector convenience.
📈 Guggenheim raised price target to $351 while maintaining Neutral rating ahead of April 30 earnings release.
⚠ Some analysts favor AI stocks over Amgen despite company's undervalued Dow component status and positive safety profile.
📈 Guggenheim raised its price target on Amgen Inc. (AMGN) from $347 to $351, citing an updated financial model ahead of earnings.
⚖️ The firm maintains a Neutral rating on AMGN while acknowledging the stock's potential as an undervalued Dow component.
📊 First-quarter results are expected to be released after market close on April 30, following Guggenheim's model update.
💉 Amgen announced positive Phase 3 trial results for TEPEZZA in patients with moderate-to-severe active thyroid eye disease on April 6.
🎯 The trial achieved its primary endpoint with a 77% proptosis response rate compared to 19.6% for placebo over 24 weeks.
👁️ Patients using the new subcutaneous injector showed an average mean eye bulge reduction of -3.17 mm versus -0.80 mm for placebo.
🔬 Secondary endpoints were also met, including improvements in diplopia outcomes, disease activity scores, and quality-of-life measures.
⚕️ Safety findings were consistent with the known intravenous formulation profile, featuring mainly mild-to-moderate injection site reactions.
➡️ The subcutaneous delivery system offers a more convenient administration option compared to the established intravenous formulation.
🏢 Amgen is a leading global biotechnology company focused on oncology, cardiovascular disease, inflammation, bone health, and rare diseases.
⚠️ Some analysts suggest AI stocks offer greater upside potential with less downside risk compared to AMGN currently.
📰 TheFly reported the analyst action and trial results as part of broader coverage on biotech and undervalued stocks.
Bullish Signals
Guggenheim raised price target to $351 ahead of Q4 earnings.
TEPEZZA Phase 3 trial met primary endpoint with 77% response rate.
Clinical trial showed improvements in diplopia and quality-of-life measures.
Subcutaneous delivery offers convenient administration comparable to IV formulation.
Safety profile remains mild with no treatment discontinuations.
Amgen continues innovating across oncology, cardiovascular, and rare diseases.
Analysts update model before Q1 earnings on April 30.
AI stocks offer better upside and lower risk than AMGN.
Competitive concerns outweigh explicit risks at present.
Bullish Signals
Guggenheim increased Amgen's price target from $347 to $351, reflecting updated optimism ahead of the company's first-quarter earnings expected after market close on April 30.
Amgen announced positive Phase 3 results for TEPEZZA using a subcutaneous on-body injector, achieving its primary endpoint with a 77% proptosis response rate versus 19.6% for placebo over 24 weeks.
The clinical trial for TEPEZZA demonstrated significant improvements in diplopia outcomes, disease activity scores, quality-of-life measures, and overall responder rates with statistically significant benefits.
The subcutaneous delivery system offered a more convenient administration option while maintaining strong clinical performance comparable to the established IV formulation.
Amgen's safety profile remained consistent with mild-to-moderate injection site reactions and no treatment discontinuations, indicating favorable risk management for this therapy.
As a leading global biotechnology company, Amgen continues to innovate in oncology, cardiovascular disease, inflammation, bone health, and rare diseases using advanced biologics and genetic science.
Risk Factors
Guggenheim maintained a Neutral rating on Amgen Inc. (AMGN) despite increasing the price target, indicating uncertainty about future upside potential.
The firm is updating its financial model ahead of first-quarter results expected after market close on April 30, suggesting that upcoming earnings could introduce volatility or disappointment.
Analysts argue that certain AI stocks offer greater upside potential and carry less downside risk compared to AMGN, reflecting competitive concerns in the investment landscape.
There are no significant risks explicitly highlighted beyond analyst preference for AI exposure over biotech investments at present.
Amgen has announced the retirement of David M. Reese, who served as Executive Vice President and Chief Technology Officer, effective June 30, 2026. Dr. Reese joined the company in 2005 as a clinical development leader in oncology and previously led Research and Development from 2018 to 2023. During his tenure, he oversaw approvals for numerous innovative medicines and biosimilars while advancing the research pipeline. Notably, as the inaugural CTO, Reese championed the early adoption of technology and artificial intelligence across the business, particularly within R&D operations. His departure is framed as part of a strategic evolution to deepen the integration of biology and technology, supporting the company's "convergent innovation" strategy that combines these fields to accelerate medicine discovery and patient engagement.
To facilitate this transition and maintain organizational momentum, Amgen outlined several executive appointments effective June 1, 2026. James Bradner, M.D., a physician-scientist with expertise in emerging technologies, will serve as Executive Vice President of Research and Development, Artificial Intelligence and Data, leveraging his experience to advance biomedical research with new tools. Sean Bruich will assume the role of Senior Vice President and Chief Technology Officer, building on his career leading global insights and AI organizations during industry transformation periods. Additionally, Murdo Gordon has been named Executive Vice President of Amgen Global Markets and Policy, a role encompassing medical, commercial operations, government affairs, and policy, drawing on his track record of strengthening health system partnerships.
The company also retained Dr. Paul Burton as Senior Vice President and Chief Medical Officer to continue focusing on reaching clinicians and patients with medicines for unmet needs in areas ranging from cardiovascular disease to rare diseases. CEO Robert A. Bradway stated that the capabilities built during Reese's tenure position Amgen to strengthen its ability to serve patients globally through convergent innovation. This restructuring aims to better connect biology, data science, and advanced technologies throughout the company's operations, supporting Amgen's mission to treat diseases such as cancer, inflammatory conditions, obesity-related conditions, and heart disease while maintaining its reputation for innovation and workplace culture.
👴 David Reese retires as CTO effective June 30, 2026.
🤖 James Bradner succeeds Reese leading R&D, AI, and Data.
🧬 New leaders advance science-tech integration and global policy roles.
💼 Amgen continues broad pipeline focus on cancer and rare diseases.
🏆 Company retains top market index honors and innovation awards.
👴 Amgen announces the retirement of David M. Reese, Executive Vice President and Chief Technology Officer, effective June 30, 2026.
🔬 Reese joined Amgen in 2005 and previously served as Executive Vice President of Research and Development from 2018 to 2023.
💡 During his tenure, Reese led approvals of innovative medicines and biosimilars while advancing the company's pipeline and discovery research capabilities.
🤖 As inaugural Chief Technology Officer, Reese championed the early adoption of technology and artificial intelligence across Amgen's business operations.
🤝 CEO Robert A. Bradway praised Reese for recognizing the impact of biology-technology convergence and positioning Amgen for future patient care.
🚀 Effective June 1, 2026, James Bradner will become Executive Vice President of Research and Development, Artificial Intelligence and Data.
📊 Sean Bruich is set to serve as Senior Vice President, Chief Technology Officer, leveraging his expertise in global insights and AI organizations.
🏛️ Murdo Gordon will take on the role of Executive Vice President for Amgen Global Markets and Policy, including Medical and Commercial Operations.
🩺 Paul Burton will continue serving as Senior Vice President and Chief Medical Officer to reach clinicians with medicines in unmet need areas.
🧬 The organizational changes are designed to deepen the integration of science and technology across Amgen's ecosystem.
💼 Amgen continues to focus on a broad pipeline treating cancer, inflammatory conditions, rare diseases, heart disease, and obesity.
🏆 The company is recognized for innovation and workplace culture, including honors from Fast Company and Forbes.
📈 Amgen remains part of the Dow Jones Industrial Average and the Nasdaq-100 Index based on market capitalization.
🌐 This press release includes standard forward-looking statements regarding collaborations, financial metrics, and regulatory outcomes.
Bullish Signals
Amgen transitions to converge biology and technology leadership.
Capabilities position company for future convergent innovation.
James Bradner joins AI and R&D executive role.
Sean Bruich continues as CTO with global insights.
Paul Burton remains CMO championing breakthrough treatments.
Pipeline targets cancer, rare diseases, heart disease and obesity.
Amgen recognized for innovation by Fast Company and Forbes.
Stock in Dow Jones and Nasdaq-100 indices.
Risk Factors
David M. Reese retires as CTO on June 30, 2026.
Transition risks threaten Amgen's convergent innovation strategy before June 1, 2026.
Uncertainty remains regarding long-term technological continuity since his 2005 tenure.
Bullish Signals
The retirement of David M. Reese marks a strategic transition that emphasizes the integration of biology and technology at Amgen.
Robert A. Bradway noted that capabilities built under Reese's tenure position the company to advance 'convergent innovation' and better serve patients in the years ahead.
James Bradner is stepping into the new role of Executive Vice President, Research and Development, Artificial Intelligence and Data, bringing expertise at the intersection of biology and technology.
Sean Bruich will continue as Senior Vice President, Chief Technology Officer, building on a career leading global insights and AI organizations through pivotal moments of industry transformation.
Paul Burton, M.D., Ph.D., will remain Senior Vice President, Chief Medical Officer, championing medical breakthroughs in areas of unmet need from cardiovascular to rare diseases.
Amgen continues to advance a broad pipeline of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity-related conditions.
Amgen has been consistently recognized for innovation and workplace culture with honors from Fast Company and Forbes.
As part of the Dow Jones Industrial Average and the Nasdaq-100 Index, Amgen remains at the cutting edge of innovation using technology and human genetic data.
Risk Factors
The retirement of David M. Reese as Executive Vice President and Chief Technology Officer effective June 30, 2026, signals a significant departure of leadership who had been pivotal in driving the early adoption of technology and artificial intelligence across the business.
This organizational change may introduce transition risks to Amgen's 'convergent innovation' strategy as new leaders assume responsibility for critical R&D and AI functions with limited time to implement immediate changes before June 1, 2026.
The announcement does not detail specific performance metrics or reasons for Reese's departure other than retirement, leaving uncertainty about the long-term continuity of the technological capabilities he built over his tenure since 2005.
Amgen announced on April 22, 2026, the retirement of David M. Reese, M.D., as executive vice president and Chief Technology Officer (CTO), effective June 30, 2026. Dr. Reese, who joined the company in 2005 as a clinical development leader in oncology, previously served as executive vice president of Research and Development from 2018 to 2023. During his tenure, he oversaw the approvals of numerous innovative medicines and biosimilars, advanced a robust pipeline of potential new therapies, and strengthened discovery research capabilities. As the inaugural chief technology officer, Dr. Reese played a pivotal role in encouraging the early adoption of technology and artificial intelligence across all facets of the business, particularly within R&D.
Robert A. Bradway, chairman and chief executive officer at Amgen, stated that Dr. Reese recognized early on the impact of advances in biology and technology on the industry and helped lead Amgen through that shift. The capabilities built under Dr. Reese's leadership are designed to advance what the company calls convergent innovation, which brings together biology, data science, and advanced technologies such as artificial intelligence to accelerate the discovery and development of new medicines. This strategic focus aims to strengthen the company's ability to serve patients in the years ahead by better connecting these interactions with how the organization operates.
To support this integration of science and technology and align with the evolving adoption of new technologies across the health care ecosystem, Amgen is implementing organizational changes effective June 1, 2026. These changes deepen the integration of biology and technology to support Amgen's ability to serve more patients around the world. Founded over 45 years ago in Thousand Oaks, California, Amgen remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. The company is advancing a broad and deep pipeline of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease, and obesity-related conditions.
Amgen has been consistently recognized for its innovation and workplace culture, including honors from Fast Company and Forbes. It is one of the 30 companies comprising the Dow Jones Industrial Average and part of the Nasdaq-100 Index. The press release also includes standard forward-looking statements regarding expectations, benefits of collaborations, potential acquisitions such as ChemoCentryx, Inc., Dark Blue Therapeutics, Ltd., or Horizon Therapeutics plc, and performance metrics like revenues and operating margins. These statements note significant risks and uncertainties that could cause actual results to differ materially from projections, including factors such as clinical and regulatory developments, competition, manufacturing difficulties, global economic conditions, and reimbursement policies.
👴 CTO David Reese retiring effective June 30, 2026 after 20-year tenure.
⚡ Organizational restructuring June 1, 2026 deepens biology and technology integration.
💊 Focus remains on cancer, inflammation, rare diseases, heart disease, and obesity.
👴 Amgen announced the retirement of David M. Reese, Executive Vice President and Chief Technology Officer, effective June 30, 2026.
💼 Dr. Reese joined Amgen in 2005 and previously served as executive vice president of Research and Development from 2018 to 2023.
🧬 During his tenure, he led approvals of innovative medicines and biosimilars while advancing the company's pipeline and discovery research capabilities.
🤖 As inaugural CTO, Reese championed early adoption of technology and artificial intelligence across Amgen's business, particularly in R&D.
🗣️ CEO Robert A. Bradway credited Reese with helping lead Amgen through the shift driven by advances in biology and technology.
⚡ The company is implementing organizational changes effective June 1, 2026, to deepen the integration of science and technology.
🔄 These changes align Amgen's structure with convergent innovation, combining biology, data science, and advanced technologies.
🌍 Strategic adjustments support Amgen's ability to serve more patients around the world through better connectivity across operations.
💊 Amgen continues to focus on developing medicines for cancer, inflammatory conditions, rare diseases, heart disease, and obesity.
📈 The company remains at the cutting edge of innovation using technology and human genetic data to push beyond current medical knowledge.
🏆 Amgen has received honors from Fast Company and Forbes for its innovation and workplace culture.
📉 As a component of both the Dow Jones Industrial Average® and the Nasdaq-100 Index®, the company represents one of the 30 largest non-financial firms.
⚠️ Investors should note that this announcement includes forward-looking statements subject to significant risks and uncertainties.
Bullish Signals
David M. Reese led approval of numerous innovative medicines.
Reese drove AI adoption across R&D as inaugural CTO.
June 1, 2026 changes deepen science-tech integration for faster discovery.
Bradway notes Reese's capabilities advance convergent innovation and patient service.
Amgen recognized by Fast Company and Forbes for culture.
Amgen uses genetic data to push beyond current medical knowledge.
Risk Factors
CTO David M. Reese retiring June 2026 creates leadership transition risk.
Future projections on collaborations and acquisitions may not materialize as expected.
Actual results could vary due to competition, manufacturing issues, and economic conditions.
Sales face pricing pressure, regulatory scrutiny, and reimbursement policy risks.
Operations subject to regulation increasing compliance costs and disruption risks.
No CTO replacement named until June 2026 creates technology adoption uncertainty.
Bullish Signals
David M. Reese, Executive Vice President and Chief Technology Officer at Amgen, led the approval of numerous innovative medicines and biosimilars during his tenure.
Under Reese's leadership as inaugural CTO, Amgen encouraged the early adoption of technology and artificial intelligence across all facets of the business, particularly in Research and Development.
Amgen's organizational changes effective June 1, 2026, will deepen the integration of science and technology to accelerate the discovery and development of new medicines.
CEO Robert A. Bradway noted that the capabilities built under David Reese position Amgen to advance convergent innovation and strengthen their ability to serve patients in the years ahead.
Amgen is recognized for innovation and workplace culture, including honors from Fast Company and Forbes.
The company remains at the cutting edge of innovation, using technology and human genetic data to push beyond current medical knowledge.
Risk Factors
David M. Reese, executive vice president and chief technology officer, is retiring effective June 30, 2026, introducing potential leadership transitions in the critical field of artificial intelligence and R&D.
The article includes extensive forward-looking statements regarding outcomes of collaborations with companies like BeOne Medicines Ltd., acquisitions including Horizon Therapeutics plc, and product performance that may not materialize as expected.
Actual results could differ materially from projections due to competition from other products including biosimilars, manufacturing difficulties or delays, and global economic conditions resulting from geopolitical relations and government actions.
Sales of products are affected by pricing pressure, political and public scrutiny, reimbursement policies imposed by third-party payers such as governments and private insurance plans, and healthcare cost containment trends.
Research, testing, pricing, marketing, and other operations are subject to extensive regulation, increasing the risk of compliance costs or operational disruptions.
The announcement lacks information on a replacement candidate for Chief Technology Officer until June 30, 2026, creating uncertainty about continuity of Amgen's technology adoption strategy during the interim period.
The article reports that Bernstein analyst Courtney Breen has maintained a Hold rating on Amgen (AMGN) while setting a price target of $335.00, a decision announced on April 22. Breen focuses on the Healthcare sector and typically covers major players like Eli Lilly & Co, Moderna, and Merck & Company, with TipRanks data indicating he has an average return of 15.3% and an 81.25% success rate on his recommended stocks. This rating follows another Hold from Barclays analyst Emily Field in a report issued on the same day, though it contrasts with Bank of America Securities' Sell rating, which was reiterated on April 15 for the same stock.
Underlying the analyst sentiment is Amgen's latest earnings release covering the quarter ending December 31. The company reported quarterly revenue of $9.9 billion and a net profit of $1.33 billion. This represents a significant increase compared to the previous year, where Amgen earned $9.09 billion in revenue and $627 million in net profit, highlighting a substantial growth in profitability alongside revenue expansion. The news content was syndicated from TipRanks and includes standard disclaimers noting that the Globe and Mail has not reviewed third-party materials and may receive compensation for the content placement.
🏦 Bank of America downgraded Amgen to Sell despite revenue growth of 9%.
💰 Net profit surged from $627M to $1.33B in the latest quarter.
🔍 Analyst consensus remains Hold with Bernstein maintaining a $335 price target.
📈 Revenue increased to $9.9B from $9.09B year-over-year.
⚠ Barclays also issued a Hold rating on the biotech stock today.
🔍 Bernstein analyst Courtney Breen maintained a Hold rating on Amgen (AMGN) with a price target of $335.00.
📊 Quarterly revenue reached $9.9 billion, representing growth from $9.09 billion in the prior year period.
💰 Net profit improved significantly to $1.33 billion compared to $627 million during the same last-year quarter.
🏦 Bank of America Securities reiterated a Sell rating on Amgen as of April 15, contrasting with recent analyst consensus.
👩💼 Bernstein covers major healthcare peers including Eli Lilly, Moderna, and Merck & Company under Breen’s portfolio.
🎯 Analyst Courtney Breen has an average return of 15.3% and an 81.25% success rate on recommended stocks historically.
📉 Barclays analyst Emily Field also issued a Hold rating on Amgen in a separate report released today.
Bullish Signals
Amgen quarterly revenue reached $9.9B, up from $9.09B last year.
Net profit hit $1.33B this quarter, more than doubling prior year's $627M.
Risk Factors
Analysts hold ratings despite positive earnings.
Bank of America maintained a sell rating.
Barclays shows mixed sentiment on stock.
Recent downgrades reflect valuation concerns.
Bullish Signals
Amgen reported quarterly revenue of $9.9 billion, representing significant growth compared to last year's revenue of $9.09 billion.
The company generated a net profit of $1.33 billion this quarter, more than doubling the net profit of $627 million from the previous year.
Risk Factors
Bernstein analyst Courtney Breen maintained a Hold rating on Amgen, downgrading expectations by not upgrading despite positive earnings, with a price target set at $335.00.
Bank of America Securities reiterated a Sell rating on Amgen as recently as April 15, signaling continued concerns among major financial institutions.
Amgen received an additional Hold rating from Barclays analyst Emily Field, indicating mixed sentiment and lack of strong confidence in near-term upside.
The stock has been downgraded to a Sell rating by Bank of America just days after the quarterly report, potentially reflecting underlying valuation or growth concerns despite reported financial gains.
Amgen Inc. (NASDAQ:AMGN) has been highlighted as one of seven of the most profitable value stocks to consider buying, following significant positive clinical data released on April 6. The biotechnology company announced successful topline results from a Phase 3 trial evaluating a subcutaneous formulation of its drug TEPEZZA for patients with moderate-to-severe active Thyroid Eye Disease. The study utilized an on-body injector to administer the medication every two weeks, demonstrating efficacy comparable to the currently approved intravenous/IV version.
The trial achieved its primary endpoint, with 77% of participants experiencing a significant proptosis response, representing a substantial reduction in eye bulging compared to approximately 20% in the placebo group. Secondary endpoints also indicated clinically meaningful improvements, including a mean proptosis reduction of 3.17 mm at week 24 and enhanced quality-of-life scores. The subcutaneous option is designed to offer a more convenient delivery method for over 25,000 patients who have historically relied on IV infusions, while maintaining a safety profile consistent with the established intravenous version, aside from some mild-to-moderate injection site reactions.
Beyond the clinical updates, Amgen operates as a drug manufacturer delivering human therapeutics through pharmaceutical wholesale distributors and is headquartered in California, having been founded in 1980. The article concludes with a perspective suggesting that while Amgen presents investment potential, certain AI stocks are viewed by the author as offering greater upside potential with less downside risk, specifically those benefiting from tariffs and onshoring trends. Readers are directed to further reports on short-term AI stock picks and Cathie Wood's 2026 portfolio recommendations.
📈 Amgen ranks among the top 7 most profitable value stocks currently.
💉 Positive Phase 3 data for TEPEZZA shows 77% significant eye bulging improvement.
🔄 New subcutaneous option replaces IV infusions for over 25,000 patients.
📈 Amgen is identified as one of the 7 Most Profitable Value Stocks to Buy Right Now.
💉 The company announced positive Phase 3 trial results for TEPEZZA, a treatment for Thyroid Eye Disease.
🩺 A subcutaneous formulation was tested using an on-body injector administered every two weeks.
📊 77% of participants achieved significant improvement in eye bulging compared to ~20% in the placebo group.
🔍 Secondary endpoints showed clinically meaningful improvements, including a 3.17 mm mean proptosis reduction at week 24.
😊 Enhanced quality-of-life scores and positive responses in double vision were also observed.
🔄 The new subcutaneous option aims to replace IV infusions for over 25,000 patients seeking more convenient access.
⚠️ Safety profiles remained consistent with the established IV version, with only mild-to-moderate injection site reactions noted.
💼 Amgen is a drug manufacturer headquartered in California, founded in 1980 and operates through pharmaceutical distributors.
🧠 The article suggests AI stocks may offer greater upside potential than AMGN despite its profitable status.
🗣️ Readers are directed to free reports on short-term AI stocks benefiting from tariff policies.
🔗 Additional reading includes a list of 33 stocks expected to double in three years and Cathie Wood's 2026 portfolio.
Bullish Signals
Amgen announced positive top line results from Phase 3 trial of TEPEZZA on April 6.
.
Trial met primary endpoint: 77% vs 20% placebo for proptosis response.
.
Mean proptosis reduced 3.17mm at week 24 with enhanced quality of life.
.
Subcutaneous delivery offers convenience for 25,000+ patients currently using IV infusions.
.
Safety profile consistent with IV, showing only mild-to-moderate injection site reactions.
.
Risk Factors
Article lacks positive details on stock potential.
Amgen has less upside than AI stocks.
Bullish Signals
On April 6, Amgen announced positive topline results from a Phase 3 trial evaluating a subcutaneous formulation of TEPEZZA for patients with moderate-to-severe active Thyroid Eye Disease.
The trial successfully met its primary endpoint, with 77% of participants achieving a significant proptosis response compared to only approximately 20% in the placebo group.
Secondary endpoints showed clinically meaningful improvements, including a mean proptosis reduction of 3.17 mm at week 24 and enhanced quality-of-life scores.
The subcutaneous formulation could evolve the standard of care by offering a more convenient and accessible delivery method for the 25,000+ patients who have historically relied on IV infusions.
The safety profile for the subcutaneous administration was generally consistent with the established IV profile, with only mild-to-moderate injection site reactions reported.
Risk Factors
The article does not provide positive details that may mislead readers about the stock's potential.
Amgen is suggested as having less upside potential compared to AI stocks, which could indicate concerns about its growth trajectory or competitive positioning in emerging sectors.
This article from Quiver Quantitative reports that Tiber Creek Health Strategies Inc. disclosed a lobbying expense of $50,000 on behalf of Amgen Inc. While the text provides no further details about the specific lobbying activities or the timing of the disclosure beyond this announcement, it indicates that a financial disclosure has been made linking Amgen to this significant lobbying spend through a third-party firm.
The content of the provided article appears to be heavily corrupted by a "No Internet" connection error message from Google News, which displays browser console data such as loading indicators like "Start slower," network troubleshooting suggestions including "Checking the network cables, modem and router," and accessibility descriptions for a placeholder "Dino game." Due to these technical errors and the lack of substantive text regarding Amgen's operations, market performance, or specific legislative targets associated with the lobbying expenditure, further analysis is not possible based on this source.
The primary factual takeaway from the available text is the specific monetary figure of $50,000 attributed to Tiber Creek Health Strategies Inc. representing Amgen Inc., though additional context regarding the nature of the lobbying efforts or the dates surrounding this disclosure was not discernible within the readable portions of the content.
🌐 No internet connection detected while loading article.
⚠️ Check network cables, modem, or router for issues.
❓ Displayed Wi-Fi reconnection suggestions on the page.
💻 news.google.com content currently unavailable for loading.
🌐 No internet connection detected while attempting to load the article.
⚠️ Connection issues require checking network cables and modem or router.
❓ Wi-Fi reconnection suggestions were displayed on the page.
💻 The news.google.com content is unavailable for loading.
Bullish Signals
Article contains no positive financial data.
Message shows system error, not news.
Risk Factors
Page inaccessible due to ERR_INTERNET_DISCONNECTED.
Bullish Signals
The article does not contain any positive financial information about Amgen as it appears to be a system error message indicating no internet connection rather than a news update.
Risk Factors
Error message 'ERR_INTERNET_DISCONNECTED' indicates the content could not be loaded, making the article inaccessible for analysis.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)